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ttp://dx.doi.org/10.1016/j.ajpath.2013.07.012Bile acids play a critical role in liver injury and regeneration, but their role in acetaminophen (APAP)e
induced liver injury is not known. We tested the effect of bile acid modulation on APAP hepatotoxicity
using C57BL/6 mice, which were fed a normal diet, a 2% cholestyramine (CSA)econtaining diet for bile
acid depletion, or a 0.2% cholic acid (CA)econtaining diet for 1 week before treatment with 400 mg/kg
APAP. CSA-mediated bile acid depletion resulted in signiﬁcantly higher liver injury and delayed
regeneration after APAP treatment. In contrast, 0.2% CA supplementation in the diet resulted in
a moderate delay in progression of liver injury and signiﬁcantly higher liver regeneration after APAP
treatment. Either CSA-mediated bile acid depletion or CA supplementation did not affect hepatic
CYP2E1 levels or glutathione depletion after APAP treatment. CSA-fed mice exhibited signiﬁcantly
higher activation of c-Jun N-terminal protein kinases and a signiﬁcant decrease in intestinal ﬁbroblast
growth factor 15 mRNA after APAP treatment. In contrast, mice fed a 0.2% CA diet had signiﬁcantly
lower c-Jun N-terminal protein kinase activation and 12-fold higher ﬁbroblast growth factor 15 mRNA
in the intestines. Liver regeneration after APAP treatment was signiﬁcantly faster in CA dietefed mice
after APAP administration secondary to rapid cyclin D1 induction. Taken together, these data indicate
that bile acids play a critical role in both initiation and recovery of APAP-induced liver injury.
(Am J Pathol 2013, 183: 1518e1526; http://dx.doi.org/10.1016/j.ajpath.2013.07.012)Supported by NIH-NIDDK grant R01 DK98414 and American Associ-
ation for the Study of Liver Diseases/American Liver Foundation Liver
Scholar Award (U.A.).
B.B. and P.B. contributed equally to this work.Bile acids are versatile biological molecules that regulate
energy homeostasis, activate nuclear receptors and cell sig-
naling pathways, and control cell proliferation and inﬂam-
matory processes in the liver and gastrointestinal tract.1,2 Bile
acids maintain their own homeostasis by activating a com-
plex signaling network involving hepatic and intestinal
farnesoid X receptor (FXR), small heterodimer partner, and
intestinal ﬁbroblast growth factor (FGF) 15 (FGF19 in
human) expression, culminating in inhibition of the primary
bile acidesynthesizing enzyme, CYP7A1.3e6 Although bile
acids are potent signaling molecules at pathophysiological
concentrations, they cause apoptosis, necrosis, and oxida-
tive stress.3,7e10 Bile acids have also been implicated in
stimulation of liver regeneration.11e14 Studies in recent
years indicate that the bile acidemediated gut-liver
signaling axis may play a critical role in regulation of
liver homeostasis.6,15,16
Acetaminophen (APAP) is the most commonly used
analgesic and antipyretic agent.17 An overdose of APAP
is the major cause of acute liver failure in the Unitedstigative Pathology.
.States.18,19 The mechanisms of APAP-induced liver injury
and subsequent liver regeneration are the focus of intense
investigation.20e22 In an overdose situation, excess APAP is
mainly metabolized by CYP2E1 to a reactive metabolite, N-
acetyl-p-benzoquinone imine (NAPQI). In hepatocytes,
conjugation of NAPQI to GSH is the key mechanism for
detoxiﬁcation of NAPQI. Once the GSH is depleted,
NAPQI attacks cellular proteins, especially mitochondrial
proteins, to form protein adducts. This triggers a cascade of
intracellular signaling events involving c-Jun N-terminal
protein kinase (JNK) activation and mitochondrial per-
meability transition, ﬁnally culminating in necrotic cell
death.20 Liver injury is followed by compensatory liver re-
generation, which is a critical determinant of ﬁnal outcome
of liver injury.23 Despite decades of research, how these
Bile Acids and APAP Hepatotoxicityintracellular events are affected by extracellular signaling is
not known.
The current study was designed to explore the role of bile
acids in initiation of liver injury and stimulation of liver
regeneration after APAP overdose. These studies are highly
signiﬁcant because the data reveal a novel role of bile acids
in cellular protection and liver regeneration after APAP
overdose, and these studies investigate the effect of resin-
mediated bile acid depletion, a commonly used therapy, on
APAP toxicity.
Materials and Methods
Animals, Treatments, and Tissue Collection
The C57BL/6 mice were obtained from Jackson Laborato-
ries (Bar Harbor, MN). Two-month-old male mice (nZ 5 to
8 per group per time point) were used in these studies. All
animal studies were approved by and performed in accor-
dance with the Institutional Animal Care and Use Com-
mittee at University of Kansas Medical Center (Kansas
City). Mice were fed a normal diet, a 2% cholestyramine
(CSA)econtaining diet, or a 0.2% cholic acid (CA)econ-
taining diet for 1 week. After a 1-week feeding of speciﬁc
diets, mice were injected i.p. with 400 mg/kg APAP (Sigma,
St. Louis, MO) dissolved in warm sterile saline solution.
Mice were not fasted before APAP treatment. Mice were
sacriﬁced at 0, 1, 4, 8, 12, and 24 hours after APAP treat-
ment, and livers, intestines, and serum were collected and
processed as previously described.14
Histological and IHC Data
Parafﬁn-embedded liver sections (4 mm thick) were used for
H&E staining and immunohistochemical (IHC) detection of
proliferating cell nuclear antigen (PCNA), as previously
described.14 H&E-stained slides were used for necrosis
scoring, as previously described,24 and PCNA-stained slides
were used for PCNA scoring, as previously described.25
Protein Extraction, Microsome Preparation, and
Western Blot Analysis
Protein extracts were prepared from frozen liver tissues using
radioimmunoprecipitation assay buffer, containing fresh
protease and phosphatase inhibitors, and used for Western
blot analysis, as previously described.14 Primary and sec-
ondary antibodies were purchased from Cell Signaling
Technologies (Danvers, MA).
Microsomes were prepared from murine liver by homog-
enizing tissue using a Teﬂon homogenizer in phosphate
buffer (pH 7.4) and centrifuged at 9000 g for 30 minutes at
4C. The supernatant from this centrifugation was centri-
fuged at 100,000 g for 60 minutes at 4C. The microsomal
pellet was resuspended in phosphate buffer with 0.1 mmol/L
EDTA (pH 7.4). Microsomes (50 mg) were used for CYP2E1
Western blot analysis.The American Journal of Pathology - ajp.amjpathol.orgReal-Time PCR Analysis
Total RNA was extracted from all murine intestines using
TRIzol, per the manufacturer’s protocol (Sigma), and reverse
transcribed as previously described.14 FGF15 mRNA levels
were determined by real-time PCR assays on the Applied
Biosystems Prism 7300 Instrument (Grand Island, NY), as
previously described.14 18S RNA levels were used for data
normalization.
Serum ALT Measurement
Serum alanine aminotransferase (ALT) was measured by
kinetic assay method using the Inﬁnity ALT kit (Thermo
Scientiﬁc, Waltham, MA), according to the manufacturer’s
protocol.
Bile Acid Analysis
Serum, liver, and intestinal total bile acids were measured
enzymatically using a Total Bile Acid Assay Kit (BQ kits, San
Diego, CA), per the manufacturer’s protocol. Brieﬂy, in
a 96-well plate, 20 mL of bile acid standard and murine serum
sampleswere added in triplicate.Diaphorase in phosphate buffer
(150 mL) was then added and incubated at 37C for 4 minutes.
After adding 30 mL of 3-a-hydroxy steroid dehydrogenase in
Tris buffer, absorbance was measured at 540 nm kinetically for
5 minutes. Speciﬁc hepatic bile acids were analyzed by Ultra
Performance Liquid Chromatography-Mass Spectrometry
(Waters, Milford, MA), as previously described.14
Glutathione Analysis
Total GSH was measured in liver homogenates by the 5,50-
dithiobis-(2- nitrobenzoic acid)-glutathione reductase recy-
cling assay (Sigma). Brieﬂy, total glutathione disulﬁde
(GSH) was extracted from liver homogenates in 5% sulfo-
salicylic acid and oxidized to GSSG by 5,50-dithiobis-(2-
nitrobenzoic acid). After adding NADPH, the rate of GSH
formation in the presence of glutathione reductase was
measured kinetically at 412 nm.
Statistical Analysis
All data presented as bar graphs are expressed as means 
SEM. An unpaired Student’s t-test was used to evaluate
statistically signiﬁcant differences between groups. P <
0.05 was considered statistically signiﬁcant.
Results
Increase in APAP-Induced Liver Injury and Delayed
Liver Regeneration after Cholestyramine-Mediated Bile
Acid Depletion
The CSA-fed mice showed a rapid and higher liver injury
within 1 hour after APAP treatment compared with control1519
Figure 1 Increased acetaminophen (APAP)-induced liver injury after bile acid depletion. A: Representative photomicrographs of H&E-stained liver sections
obtained over a time course of 0 to 24 hours after APAP treatment of mice fed either a normal diet or a 2% CSA diet. B: Serum ALT activity measured over
a time course of 0 to 24 hours after APAP treatment of mice fed either a normal diet or a 2% CSA diet. C: Percentage necrosis after APAP treatment. D:
Percentage PCNA-positive cells at 12 and 24 hours in liver sections of APAP-treated mice fed either a normal diet or a 2% CSA diet. E: Western blot analysis of
cyclin D1 and PCNA using total liver cell extracts of normal diete or CSA dietefed mice treated with APAP. F: Representative photomicrographs of PCNA IHC
staining of liver sections of APAP-treated mice fed either a normal diet or a 2% CSA diet at 12 and 24 hours after APAP treatment. Arrowheads indicate cells in
the S phase. *P < 0.05 (BeD). GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Bhushan et almice, as demonstrated by histopathological analysis of
H&E-stained liver sections (Figure 1A), serum ALT levels
(Figure 1B), and necrosis scoring (Figure 1C). Centrilobular
necrosis was clearly evident at 4 hours after APAP treatment
in CSA-fed mice but not until 8 hours after APAP treatment
in normal dietefed mice. Peak liver injury was observed at 8
hours in both groups. Injury decreased signiﬁcantly in the
normal dietefed mice at 24 hours after APAP treatment.
Although serum ALT values declined at 24 hours in CSA-fed
mice, necrosis scoring demonstrated that signiﬁcant liver cell
death was still evident in CSA-fed mice at 24 hours after
APAP administration. Liver regeneration was studied using
PCNA analysis for determining cell proliferation and
Western blot analysis of cyclin D1 and PCNA (Figure 1,
DeF). PCNA staining (Figure 1, D and F) and cyclin D1
Western blot data (Figure 1E) indicate that the CSA-fed mice
experienced a delay in initiation of liver regeneration after
APAP overdose and exhibited signiﬁcantly lower cell
proliferation at 12 hours after APAP administration.
However, this delay in cell proliferation was overcome by 24
hours after APAP treatment, and both normal dietefed and
CSA-fed mice had similar liver regeneration.
Mechanisms of Increased APAP-Induced Injury after
Bile Acid Depletion
To determine the mechanism behind increased APAP-
induced cell injury in CSA-fed mice, we analyzed the
levels of APAP-metabolizing enzyme, CYP2E1, antioxidant
GSH, and JNK activation, which is known to be a critical
step in APAP-induced liver injury. Western blot analysis
showed no difference in microsomal CYP2E1 expression1520between CSA dietefed mice and normal dietefed mice
(Figure 2A). Analysis of total GSH levels in liver revealed
that CSA diet feeding did not have any effect on hepatic
GSH levels before APAP treatment. Furthermore, similar
GSH depletion (90% for control) was observed at 1 hour
after APAP treatment in both normal diete and CSA-fed
mice (Figure 2B). Interestingly, the recovery of hepatic
GSH was signiﬁcantly delayed in the CSA dietefed mice
after APAP administration (Figure 2C). By 12 hours, the
normal dietefed mice had recovered GSH up to 60% of the
pre-APAP levels, but the CSA dietefed mice had recovered
only 30% of their pre-APAP levels. Western blot analysis of
total and phosphorylated JNK indicated signiﬁcant activa-
tion of JNK in CSA-fed mice within 1 hour after APAP
treatment, which further increased and was higher than the
normal dietefed mice at 4 hours after APAP administration
(Figure 2D). In contrast, JNK activation was evident in
normal dietefed mice only at 4 hours after APAP treatment.Changes in Bile Acid Composition in Livers of CSA-Fed
Mice
Next, we determined changes in total bile acid levels in
serum, liver, and intestine in normal dietefed and CSA-fed
mice. The data indicate a signiﬁcant decrease in serum,
hepatic, and intestinal bile acid levels after CSA treatment
(Figure 3, AeC). We further quantiﬁed speciﬁc bile acid
species in the livers of normal dietefed and CSA-fed mice,
which indicated a signiﬁcant decrease in tauro-b-muricholic
acid and u-muricholic acid in CSA-fed mice (Figure 3,
DeG).ajp.amjpathol.org - The American Journal of Pathology
Figure 2 Mechanisms of increased acetamin-
ophen (APAP)-induced injury after bile acid
depletion. A: Western blot analysis of microsomal
CYP2E1 using total liver cell extract of normal diet
(ND)efed and cholestyramine (CSA)-fed murine
livers obtained before APAP treatment at 0 hours.
B: GSH levels in the livers of ND-fed (black bars)
and CSA-fed (gray bars) mice during a time course
of 0 to 12 hours after APAP treatment. C:
Percentage of GSH depletion in the livers of
control (black bars) and CSA-fed (gray bars) mice
during a time course of 0 to 12 hours after APAP
treatment. D: Western blot analysis of total and
phosphorylated JNK using total liver cell extracts
of ND-fed and CSA-fed murine livers obtained at
various time points after APAP treatment. *P <
0.05 (B and C). GAPDH, glyceraldehyde-3-
phosphate dehydrogenase.
Bile Acids and APAP HepatotoxicitySigniﬁcant Inhibition of Intestinal FGF15 Expression
after CSA Treatment
Bile acids are known to regulate their own biosynthesis via
the liver-gut FXR-FGF15 signaling axis. Bile acids are
absorbed in the ileal cells, where they activate FXR, which,
in turn, stimulates FGF15 expression and secretion. FGF15
comes to liver via portal circulation and via binding to
FGF receptor 4, inhibits hepatic CYP7A1 expression, andFigure 3 Changes in total bile acids (TBAs) and intestinal FGF15 mRNA after C
normal dietefed (black bars) or CSA-diet (gray bars) fed mice. UPLC-MSemediate
(MCA; D), tauro-b-muricholic acid (TCA; E), tauro-b-MCA (F), and u-MCA (G). Seru
analysis. H: Real-time PCR analysis of FGF15 mRNA in the intestine of control and
FGF15 mRNA in the intestine of control and CSA-fed mice at various time points
The American Journal of Pathology - ajp.amjpathol.orgdown-regulates bile acid synthesis. The effect of CSA-
mediated bile acid reduction on intestinal FGF15 expression
in normal dietefed and CSA dietefed mice was determined
using real-time PCR. The data indicate that CSA-fed mice
had >500-fold lower intestinal FGF15 than normal dietefed
mice, even before APAP treatment (Figure 3H). After
APAP treatment, FGF15 gene expression decreased
signiﬁcantly by 8 hours after APAP treatment but returned
to pre-APAP levels by 24 hours after APAP treatment inSA treatment. Total bile acids in serum (A), liver (B), and intestines (C) in
d quantiﬁcation of speciﬁc hepatic bile acids, including a-muricholic acid
m and liver samples at 0 hours before APAP administration were used for the
CSA-fed mice before APAP treatment at 0 hours. I: Real-time PCR analysis of
after APAP treatment. *P < 0.05 (AeC and FeH).
1521
Figure 4 Cholic acid supplementation delays
initiation of injury and stimulates rapid recovery
after APAP treatment. A: Representative photo-
micrographs of H&E-stained liver sections of
normal diete and 0.2% CA dietefed mice treated
with APAP during a time course of 0 to 24 hours.
B: Serum ALT levels in normal dietefed (black
bars) and 0.2% CA dietefed mice (gray bars)
treated with APAP. C: Percentage of cells in
necrosis in the livers of normal dietefed (black
bars) and 0.2% CA dietefed mice (gray bars)
treated with APAP. *P < 0.05 (B and C).
Bhushan et alnormal dietefed mice. In contrast, FGF15 expression
remained extremely low to undetectable throughout the time
course after APAP treatment in CSA-fed mice (Figure 3I).
Delayed Initiation and Rapid Resolution of
APAP-Induced Liver Injury in 0.2% CA DieteFed Mice
To determine whether bile acid supplementation modulates
APAP hepatotoxicity, we fed C57BL/6 mice either a normal
diet or a 0.2% CA diet for 1 week before treatment of 400
mg/kg of APAP. Liver injury was determined using serum
ALT levels (Figure 4B) and necrosis scoring of H&E-
stained parafﬁn sections (Figure 4, A and C). CA dietefed
mice showed a moderate increase in serum ALT levels
before APAP treatment, which continued at 1 hour after
APAP treatment. However, necrosis was not evident in
histological examinations in CA dietefed mice before (0
hours) and 1 hour after APAP treatment. After APAP
treatment, CA dietefed mice exhibited a delayed initiation
of liver injury, as shown by a lower (but not statistically
signiﬁcant) serum ALT level and necrosis score at 4 hours,
which were statistically signiﬁcant. However, liver injury
increased thereafter and was similar in normal dietefed and
CA dietefed mice at its peak at 12 hours. Interestingly,
APAP-induced liver injury decreased much faster and was
signiﬁcantly lower at 24 hours in CA dietefed mice
compared with normal dietefed mice, as shown by lower
serum ALT levels and necrosis scores.
Mechanisms of Delayed Initiation of Liver Injury after
CA Supplementation
To determine the mechanisms of delayed initiation of
APAP-induced liver injury in CA dietefed mice, we1522determined hepatic CYP2E1 levels and GSH depletion after
APAP treatment. Western blot analysis using total cell
lysates indicated no difference in hepatic CYP2E1 protein
expression (Figure 5A). Total GSH-level analysis revealed
that cholic acid supplementation did not change hepatic
GSH content before APAP treatment. Furthermore, an equal
GSH depletion was observed in normal dietefed and CA
dietefed mice 1 hour after APAP treatment (Figure 5B).
GSH recovery was moderately faster in CA dietefed mice
after APAP administration (Figure 5C). We next determined
activation of JNK using Western blot analysis, which
showed that JNK activation was signiﬁcantly lower in CA
dietefed mice compared with normal dietefed mice after
APAP treatment (Figure 5D). Substantial JNK phosphory-
lation was observed in normal dietefed mice at 4 hours after
APAP treatment. In contrast, only moderate JNK phos-
phorylation was observed in CA dietefed mice.
Mechanisms of Rapid Recovery from APAP-Induced
Liver Injury after CA Supplementation
We further determined the level of liver regeneration after
APAP-induced liver injury using PCNA analysis and cyclin
D1 protein expression. Our data indicate a rapid and higher
increase in liver cell proliferation in CA dietefed mice after
APAP treatment (Figure 5, E and F). There was no ongoing
cell proliferation in CA dietefed mice before APAP
administration (data not shown). However, a signiﬁcant
number of hepatocytes were PCNA positive at 4 hours after
APAP treatment, which further increased at 12 and 24 hours
in CA dietefed mice. Normal dietefed mice also showed an
increase in liver regeneration, but it was signiﬁcantly slower
and at a lower extent compared with CA dietefed mice. The
increase in cell proliferation was consistent with a rapid andajp.amjpathol.org - The American Journal of Pathology
Figure 5 Mechanisms of acetaminophen
(APAP)-induced liver injury and regeneration after
cholic acid supplementation. Western blot analysis
of CYP2E1 using total liver cell extract (A), GSH
levels in the livers (B), percentage of GSH deple-
tion (C), Western blot analysis of total and phos-
phorylated JNK using total liver cell extract (D),
representative photomicrographs of PCNA IHC
staining in the livers (E), bar graph showing
percentage of PCNA-positive cells in livers (F), and
Western blot analysis of cyclin D1 using total liver
cell extracts (G) of normal diet (ND)efed and 0.2%
CA dietefed mice after APAP treatment. *P < 0.05
(B, C, and F). GAPDH, glyceraldehyde-3-phosphate
dehydrogenase.
Bile Acids and APAP Hepatotoxicityhigher increase in cyclin D1 expression in CA dietefed
mice after APAP treatment (Figure 5G).
Increase in Total Bile Acids and FGF15 mRNA in CA
DieteFed Mice
An analysis of total bile acid levels in serum, liver, and
intestines of normal dietefed and CA dietefed mice revealed
that CA supplementation substantially increased total bile
acid content in all three compartments (Figure 6, AeC).
Further analysis revealed that intestinal FGF15 mRNA was
consistently 12- to 14-fold higher in CA dietefed mice
compared with normal dietefed mice throughout the time
course of 0 to 24 hours after APAP treatment (Figure 6D).
Discussion
Overdose of APAP, the most commonly used analgesic
drug, is the main cause of acute liver failure in the Western
world.26 Despite decades of research, the mechanisms of
APAP-induced liver injury are not completely known.27
Even more complicated and unknown are the mechanisms
of APAP overdose on the background of existing diseaseThe American Journal of Pathology - ajp.amjpathol.orgconditions.27 Furthermore, the contribution of extrahepatic
factors to APAP-induced liver injury and subsequent liver
regeneration is completely unknown.
Extensive studies in the past decade have demonstrated
that bile acids are excellent signaling molecules and that bile
acid signaling is involved in several physiological and
pathological conditions.1,4 Previous studies have shown that
bile acids can signal via multiple receptors, including FXR,
TGR5, and epidermal growth factor receptor.3,4,28 At a
normal concentration, bile acids seem to be protective
against cell stress and injury, but are known to be toxic at
higher concentrations.4 Reduction of bile acids using resins,
such as cholestyramine, is a common therapy against
hypercholesterolemia and in cholestasis.29 Similarly, urso-
deoxycholic acid has been used as a treatment for several
biliary diseases.30 However, the role of bile acids in APAP-
induced liver injury is not known. Our data indicate that
depletion of bile acids using CSA results in increased
APAP-induced liver injury and slower recovery. In contrast,
supplementation of cholic acid in diet resulted in delayed
initiation of liver injury and rapid recovery after APAP
treatment. Taken together, our data indicate that bile acids
may be protective against APAP-induced liver injury.1523
Figure 6 Changes in total bile acids and FGF15 mRNA after cholic acid
supplementation. Total bile acids in serum (A), liver (B), and intestines (C)
of normal dietefed and 0.2% cholic acid (CA) dietefed mice before
acetaminophen (APAP) treatment. D: Intestinal FGF15 mRNA expression in
normal dietefed (black bars) and 0.2% CA dietefed (gray bars) mice before
and after APAP administration. *P < 0.05 (AeD).
Bhushan et alOur observations are also consistent with previous reports
in long-lived Little mice, which were shown to be protected
from APAP and bromobenzene hepatotoxicity.31 These
mice are also known to have increased bile acids, which
have been implicated in several phenotypes observed in
these mice, including prolongation of life span and protec-
tion from APAP. Furthermore, our data are also consistent
with previous studies that activation of FXR, the primary
bile acid receptor, provides protection from APAP-induced
liver injury.32 However, the mechanisms behind these ob-
servations may be different from those underlying our
observations.
Our data indicate that neither bile acid depletion by CSA
nor CA supplementation interferes with initial bioactivation
of APAP to its reactive metabolite, NAPQI. This is evident
from rapid and equal depletion of hepatic GSH after APAP
treatment in all treatment groups. Previous studies have
shown that depletion of GSH is a sensitive indicator of
APAP metabolism, especially in overdose situations.21
Recent studies indicate that GSH recovery also plays
a critical role in injury development after APAP overdose.33
It is known that GSH recovery, driven by de novo GSH
synthesis catalyzed by the enzyme glutamate-cysteine ligase
(Gclc), is delayed at higher doses of APAP, which exhibit
higher liver injury.33 Consistent with this observation, our
results showed that GSH recovery is signiﬁcantly delayed
after APAP administration in mice with CSA-mediated bile
acid depletion. Similarly, the GSH recovery was faster in
mice fed a cholic acid diet. These data indicate that bile
acids may be involved in GSH recovery after APAP over-
dose. The exact mechanisms behind this effect are not
known. It is known that Nuclear factor (erythroid-derived
2)-like 2 (Nrf2) is a major regulator of Gclc expression, and
studies have shown that bile acids can affect Nrf2 acti-
vation.34 This raises the possibility that bile acids may1524stimulate Gclc expression via Nrf2, which may be involved
in the protective effect shown by bile acids.
Hepatic JNK activation is a critical step in the intra-
cellular signaling involved in APAP-induced liver in-
jury.20,35,36 Our data show that bile acid depletion results in
rapid activation of JNK and that cholic acid supplementa-
tion results in a decreased activation of JNK compared with
normal diet control mice. These data indicate that bile acids
may suppress JNK activation during APAP-induced liver
injury. Whether bile acids directly affect JNK activation or
induce this effect via an upstream regulator is not known.
Bile acids are known to signal via multiple pathways in the
liver, including FXR, TGR5, and epidermal growth factor
receptor. It is possible that bile acids may use one of these
pathways to suppress JNK signaling after APAP-induced
liver injury.
It is known that bile acids play a critical role in the gut-
liver signaling axis by stimulating FGF15 (FGF19 in
humans) expression in the ileal cells via an FXR-dependent
mechanism.6 This gut-liver axis of FGF15 signaling has
been implicated in liver regeneration.13,14,37,38 In our stu-
dies, CSA-mediated bile acid depletion, which resulted in
exacerbation of APAP toxicity, reduced FGF15 expression
to undetectable levels. Similarly, 0.2% CA supplementation,
which resulted in delayed initiation and rapid recovery from
APAP toxicity, resulted in 15-fold up-regulation of FGF15
mRNA. These data suggest a role for FGF15 in the bile
acidemediated protection from APAP hepatotoxicity.
However, the exact role of FGF15 remains to be investi-
gated. It is possible that bile acidestimulated FGF15 has
a cytoprotective role during the initiation phase of injury.
This notion is supported by previous observations that
FGF15-knockout mice exhibited extensive liver injury after
partial hepatectomy (PHX).38 It is known that the regener-
ating lobes after PHX do not normally exhibit necrotic cell
death.39 However, recent studies have demonstrated that
FGF15-knockout mice have signiﬁcant necrosis in regen-
erating lobes after PHX,38 indicating that lack of FGF15
may remove an important cytoprotective mechanism in
hepatocytes.
Several studies have demonstrated that compensatory
liver regeneration after APAP-induced liver injury is a crit-
ical determinant of ﬁnal outcome of APAP overdose.40e44
Our data clearly demonstrate that bile acid depletion
results in delayed liver regeneration and that bile acid
supplementation stimulates rapid liver regeneration after
APAP overdose. These data are consistent with previous
observations that bile acid supplementation stimulates liver
regeneration.13 Recent studies have elegantly shown that
FGF15 may be a primary mediator of the bile acideinduced
stimulation of liver regeneration after PHX.38,45 It remains
to be seen whether these same mechanisms apply in stim-
ulating regeneration after APAP overdose.
Taken together, our data indicate that bile acids play
a central role in modulating APAP-induced liver injury and
regeneration. The observation that cholestyramine-mediatedajp.amjpathol.org - The American Journal of Pathology
Bile Acids and APAP Hepatotoxicitybile acid depletion exacerbates APAP-induced liver injury
and delays regeneration is signiﬁcant because of the routine
use of cholestyramine in clinical practice. These data suggest
a possible drug-drug interaction between APAP and CSA,
and caution should be taken in administering APAP for
patients taking CSA. Our data also indicate that bile acids
have a cytoprotective and proregenerative role in APAP-
induced liver injury, which could potentially be used for
treatment of APAP-induced patients with acute liver failure.References
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